A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease.

ABSTRACT:

Introduction

Alzheimer's disease consensus recommends biomarker dichotomization, a practice with well-described clinical strengths and methodological limitations. Although neuroimaging studies have explored alternative biomarker interpretation strategies, a formally defined three-range approach and its prognostic impact remains under-explored for cerebrospinal fluid (CSF) biomarkers .

Methods

With two-graph receiver-operating characteristics based on different reference schemes, we derived three-range cut-points for CSF Elecsys biomarkers. According to baseline CSF status, we assessed the prognostic utility of this in predicting risk of clinical progression and longitudinal trajectories of cognitive decline and amyloid-beta (Aβ) positron emission tomography (PET) accumulatio

SUBMITTER: Brum WS 

PROVIDER: S-EPMC8918110 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature